Boston Scientific Corp. on Thursday won approval from the U.S. Federal Trade Commission for its $27 billion acquisition of Guidant Corp., on condition that the company bring a new competitor to the market by selling all assets related to Guidant’s vascular business to Abbott Laboratories.

Anticipating FTC concerns about concentration in the vascular market, Boston Scientific proposed the sale to Abbott as part of its definitive buyout offer to Guidant shareholders in January.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]